1.095

1.87% 0.025

Pliant Therapeutics Inc (PLRX)

Overview News Price History Option Chain Financials Discussions Forecast

Pliant Therapeutics Inc stock is traded at $1.095, with a volume of 429.65K. It is up +1.87% in the last 24 hours and down -5.22% over the past month. Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.

Previous Close:

$1.07

Open:

$1.07

24h Volume:

429.65K

Relative Volume:

0.83

Market Cap:

$67.49M

Revenue:

$248.00K

Net Income/Loss:

$-113.22M

P/E Ratio:

-0.5946

EPS:

-1.8416

Net Cash Flow:

$-98.81M

1W Performance:

+4.81%

1M Performance:

-5.22%

6M Performance:

-3.54%

1Y Performance:

-29.68%

1-Day Range:

$1.07

$1.12

1-Week Range:

$1.02

$1.12

52-Week Range:

$1.02

$1.95

Pliant Therapeutics Inc Stock (PLRX) Company Profile

Name

Pliant Therapeutics Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

650-481-6770

Address

331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

PLRX's Discussions on Twitter

Compare PLRX vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PLRX Pliant Therapeutics Inc	1.09	66.26M	248.00K	-113.22M	-98.81M	-1.8416
VRTX Vertex Pharmaceuticals Inc	515.89	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.79	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.63	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.22	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.16	39.31B	5.76B	514.49M	1.10B	4.4813

Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-10-25	Downgrade	JP Morgan	Neutral → Underweight
Mar-04-25	Resumed	Cantor Fitzgerald	Neutral
Mar-04-25	Downgrade	Needham	Buy → Hold
Mar-03-25	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-03-25	Downgrade	Stifel	Buy → Hold
Feb-10-25	Downgrade	Canaccord Genuity	Buy → Hold
Feb-10-25	Downgrade	Citigroup	Buy → Neutral
Feb-10-25	Downgrade	H.C. Wainwright	Buy → Neutral
Feb-10-25	Downgrade	JP Morgan	Overweight → Neutral
Feb-10-25	Downgrade	Oppenheimer	Outperform → Perform
Feb-10-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Feb-10-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-09-24	Resumed	Leerink Partners	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
May-18-23	Initiated	Canaccord Genuity	Buy
Apr-13-23	Initiated	Robert W. Baird	Outperform
Dec-14-22	Initiated	Stifel	Buy
Dec-07-22	Initiated	JP Morgan	Overweight
Sep-01-22	Initiated	Citigroup	Buy
Jul-20-22	Initiated	SVB Leerink	Outperform
May-25-22	Initiated	Cantor Fitzgerald	Overweight
Dec-10-21	Initiated	Oppenheimer	Outperform
Nov-24-21	Initiated	RBC Capital Mkts	Outperform
Nov-03-21	Initiated	H.C. Wainwright	Buy
Apr-20-21	Initiated	BTIG Research	Buy
Apr-05-21	Initiated	Citigroup	Buy
Jun-29-20	Initiated	Citigroup	Buy
Jun-29-20	Initiated	Cowen	Outperform
Jun-29-20	Initiated	Needham	Buy
Jun-29-20	Initiated	Piper Sandler	Overweight

View All

Pliant Therapeutics Inc Stock (PLRX) Latest News

08:04 AM

Pliant Therapeutics (PLRX) Advances Clinical Program Amidst Chal - GuruFocus

08:04 AM

06:50 AM

Monaco Asset Management SAM Purchases Shares of 1,938,747 Pliant Therapeutics, Inc. $PLRX - MarketBeat

06:50 AM

Aug 15, 2026

Pliant Therapeutics Inc (FRA:9PT) Stock Price, Trades & News - GuruFocus

Aug 15, 2026

Pliant Therapeutics (NASDAQ:PLRX) Downgraded by Wall Street Zen to Sell - MarketBeat

Aug 15, 2026

Aug 14, 2026

Pliant Therapeutics (PLRX) gains 8.9% institutional holder in ADAR1 Capital - Stock Titan

Aug 14, 2026

Pliant Therapeutics (PLRX): Citadel entities, Kenneth Griffin report 3.5% holding - Stock Titan

Aug 14, 2026

Aug 13, 2026

Price performance - Yahoo Finance Australia

Aug 13, 2026

CCORF Maintains Pliant Therapeutics(PLRX.US) With Hold Rating, Maintains Target Price $3 - Moomoo

Aug 13, 2026

Aug 12, 2026

PLRX (Pliant Therapeutics) 12-1 Month Momentum % : -34.12% (As of Aug. 12, 2026) - GuruFocus

Aug 12, 2026

Aug 11, 2026

Pliant Therapeutics cuts Q2 loss to $22.4M on lower costs - scanx.trade

Aug 11, 2026

Form 8K Pliant Therapeutics Inc For: 11 August By Investing.com - Investing.com Nigeria

Aug 11, 2026

Pliant Therapeutics (NASDAQ:PLRX) Posts Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat

Aug 11, 2026

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results - The Manila Times

Aug 11, 2026

Pliant Therapeutics (PLRX) halves quarterly loss and reports $159.6M in cash reserves - Stock Titan

Aug 11, 2026

BRIEF-Pliant Therapeutics Q2 Net Income USD -22.371 Million - TradingView

Aug 11, 2026

Aug 09, 2026